SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

Company Overview

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: $1.78 to $1.86
• 50-Day Range: $1.50 to $2.19
• 52-Week Range: $0.77 to $2.27
• Volume: 1.01 million shs
• Average Volume: 2.66 million shs
• Market Capitalization: $179.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

SELLAS Life Sciences Group Stock Analysis - MarketRank™

SELLAS Life Sciences Group scored higher than 47% of companies evaluated by MarketBeat, and ranked 614th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

SELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.57) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SELLAS Life Sciences Group is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SELLAS Life Sciences Group is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SELLAS Life Sciences Group has a P/B Ratio of 13.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.76% of the float of SELLAS Life Sciences Group has been sold short.

Short Interest Ratio / Days to Cover

SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in SELLAS Life Sciences Group has recently increased by 28.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SELLAS Life Sciences Group does not currently pay a dividend.

Dividend Growth

SELLAS Life Sciences Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

24.76% of the float of SELLAS Life Sciences Group has been sold short.

Short Interest Ratio / Days to Cover

SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in SELLAS Life Sciences Group has recently increased by 28.89%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

SELLAS Life Sciences Group has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for SELLAS Life Sciences Group this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

3 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, SELLAS Life Sciences Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.40% of the stock of SELLAS Life Sciences Group is held by insiders.

Percentage Held by Institutions

Only 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.

SLS Stock Analysis - Frequently Asked Questions

How have SLS shares performed this year?

SELLAS Life Sciences Group's stock was trading at $1.04 at the beginning of 2025. Since then, SLS shares have increased by 73.1% and is now trading at $1.80.

How were SELLAS Life Sciences Group's earnings last quarter?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04.

When did SELLAS Life Sciences Group's stock split?

SELLAS Life Sciences Group's stock reverse split before market open on Friday, November 8th 2019.The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Who are SELLAS Life Sciences Group's major shareholders?

Top institutional shareholders of SELLAS Life Sciences Group include Blair William & Co. IL (0.02%).
View institutional ownership trends.

How do I buy shares of SELLAS Life Sciences Group?

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SELLAS Life Sciences Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include (UNISQ) (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol Myers Squibb (BMY) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/25/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLS
• CIK: 1390478
• Web: www.sellaslifesciences.com
• Phone: (646) 200-5278
• Fax: 441-400-2875
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for SELLAS Life Sciences Group: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +288.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -193.67%
• Return on Assets: -113.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.64
• Quick Ratio: 4.64

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 179.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 13.85

Miscellaneous

• Outstanding Shares: 99,780,000
• Free Float: 98,380,000
• Market Cap: $179.60 million
• Optionable: Not Optionable
• Beta: 2.31